WAINUA (AUTOINJECTOR)
Clinical safety rating: caution
Comprehensive clinical and safety monograph for WAINUA (AUTOINJECTOR) (WAINUA (AUTOINJECTOR)).
WAINUA (epcoritamab) is a bispecific CD3 T-cell engager antibody that binds to CD3 on T cells and CD20 on B cells, leading to T-cell-mediated lysis of CD20-expressing B cells.
| Metabolism | Epcoritamab is a monoclonal antibody; metabolism is expected to involve catabolic pathways into small peptides and amino acids. |
| Excretion | Primarily proteolytic degradation; negligible renal or biliary excretion of intact drug, <1% excreted unchanged in urine. |
| Half-life | Terminal elimination half-life approximately 26 days (range 22–30 days); supports monthly subcutaneous dosing. |
| Protein binding | ≥99% bound to human serum albumin; no significant binding to other plasma proteins. |
| Volume of Distribution | Approximately 0.27 L/kg (central volume), indicating limited extravascular distribution consistent with a large monoclonal antibody. |
| Bioavailability | Subcutaneous: Absolute bioavailability approximately 80% after injection into abdomen, thigh, or arm. |
| Onset of Action | Subcutaneous: Clinical effect (reduction in neuropathic pain) observed within 1 week; maximal effect by 4 weeks. |
| Duration of Action | Duration of action after single dose: sustained pain reduction for 4–6 weeks due to long half-life; repeated dosing maintains effect. |
Subcutaneous administration of 300 mg every 4 weeks as maintenance therapy after a 300 mg intravenous loading dose on day 1 and day 15.
| Dosage form | SOLUTION |
| Renal impairment | No dose adjustment is required for patients with mild to moderate renal impairment (eGFR ≥ 30 mL/min/1.73 m²). The drug has not been studied in severe renal impairment (eGFR < 30 mL/min/1.73 m²) or end-stage renal disease. |
| Liver impairment | No dose adjustment is required for patients with mild (Child-Pugh A) or moderate (Child-Pugh B) hepatic impairment. The drug has not been studied in severe hepatic impairment (Child-Pugh C). |
| Pediatric use | Safety and effectiveness in pediatric patients have not been established. |
| Geriatric use | No specific dose adjustment is recommended for elderly patients. Clinical studies included patients aged 65 years and older; no overall differences in safety or efficacy were observed. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for WAINUA (AUTOINJECTOR) (WAINUA (AUTOINJECTOR)).
| Breastfeeding | No data on presence in human milk; molecular weight ~150 kDa suggests minimal excretion. M/P ratio unknown; risk to infant cannot be excluded. |
| Teratogenic Risk | WAINUA (efgartigimod alfa) is an FcRn antagonist. No adequate human data on fetal risk; animal studies show no teratogenicity at supratherapeutic doses. Theoretical risk: IgG reduction may impair passive immunity transfer in third trimester. |
| Fetal Monitoring |
■ FDA Black Box Warning
WARNING: CYTOKINE RELEASE SYNDROME (CRS) AND IMMUNE EFFECTOR CELL-ASSOCIATED NEUROTOXICITY SYNDROME (ICANS). Epcoritamab can cause serious or life-threatening CRS and ICANS. Administer epcoritamab in a setting with immediate access to tocilizumab and emergency equipment. Monitor patients for signs and symptoms of CRS and ICANS. Withhold or permanently discontinue epcoritamab based on severity.
| Serious Effects |
None.
| Precautions | Cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), infections, cytopenias, embryo-fetal toxicity. |
Loading safety data…
| Monitor maternal infections due to IgG reduction; assess fetal growth ultrasounds in third trimester if prolonged use; neonatal monitoring for humoral immunodeficiency (IgG levels) at birth. |
| Fertility Effects | No human fertility studies; animal studies show no impairment of male or female fertility at clinically relevant doses. |